Christian Itin, formerly president and chief executive of Micromet (now Amgen Inc), has been named chief executive officer of London-based Autolus Ltd, which is developing engineered T cell therapies for haematological and solid tumours. He is also chairman of the company.
Dr Itin is a leader in immuno-oncology having pioneered the field of T cell engaging antibodies at Micromet. More recently he was CEO and chairman of Switzerland-based Cytos Biotechnology, which now trades under the name Kuros Biosciences AG. In addition to chairing Autolus, Dr Itin is chairman of Kuros and serves on the board of Kymab Ltd, a UK antibody developer.
Autolus announced the appointment on 3 March 2016.
Copyright 2016 Evernow Publishing Ltd